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Chapter 1 
 
 
AMINO ACID TRANSPORTERS 
 
 
 
1.1 Heteromeric Amino Acid Transporters  
 In the last decade, many amino acid transporters were identified by 
molecular cloning and assigned to the classically characterized amino acid 
transport systems.  
 Amino acid transporters permit the uptake of amino acids from food 
in the small intestine. They release the amino acids themselves into blood, 
and then perform either uptake of amino acids from the blood into tissues 
such as liver or skeletal muscle or they allow amino acids from the urine 
along the kidney nephron to be reabsorpted (Wagner et al., 2001). Six 
families of amino acid transporters for the cell plasma membrane have been 
described in mammals, one of which has a heteromeric structure (Franca et 
al., 2005; Palacin et al., 2005). 
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 Heteromeric amino acid transporters (HATs) are composed of a 
heavy subunit and a light subunit (Table 1.1) (Palacin et al., 2005). Two 
homologous heavy subunits (HSHATs) from the SLC3 family have been 
cloned and are called rBAT and 4F2hc (also named CD98). Ten light 
subunits (LSHATs; SLC7 family members from SLC7A5 to SLC7A13) 
have been identified. Six of them are partners of 4F2hc (LAT1, LAT2, 
y+LAT1, y+LAT2, asc-1, and xCT); one forms a heterodimer with rBAT 
(b0,+AT); and two (asc-2 and AGT-1) seem to interact with as yet unknown 
heavy subunits (Verrey et al., 2004). Members SLC7A1–SLC7A4 of family 
SLC7 correspond to system y+ isoforms (cationic amino acid transporters; 
CATs) and related proteins, which on average show <25% amino acid 
identity to the light subunits of HATs (Palacin et al., 2005). The general 
features of HATs are as follows:  
 
• The heavy subunits (molecular mass of ~90 and ~80 kDa for rBAT 
and 4F2hc, respectively) are type II membrane N-glycoproteins with 
a single transmembrane domain, an intracellular NH2 terminus, and  
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an extracellular COOH terminus significantly homologous to insect 
 and bacterial glucosidases (Fig. 1.1). Recently, X-ray diffraction of 
 the extracellular domain of human 4F2hc revealed a three-
 dimensional structure similar to that of bacterial glucosidases 
 (Palacin et al., 2005). 
• The light subunits (~50 kDa) are highly hydrophobic and not 
glycosylated. This results in anomalously high mobility in 
SDS/PAGE (35–40 kDa). Recent cysteine-scanning mutagenesis 
studies support a 12-transmembrane-domain topology, with the NH2 
and COOH terminals located inside the cell and with a reentrant-like 
structure in the intracellular loop IL2-3 for xCT, as a model for the 
light subunits of HATs (Fig. 1.1) (Gasol et al., 2004). The light chain 
and the corresponding heavy chain subunit are linked by a disulfide 
bridge. For this reason, HATs are also named glycoprotein-associated 
amino acid transporters. The light subunit cannot reach the plasma 
membrane unless it interacts with the heavy subunit. 
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1.2 Functional Proprieties of Heteromeric Amino Acid Transporters  
 The light subunit confers specific amino acid transport activity to the 
heteromeric complex. LAT1 and LAT2 correspond to system L isoforms, 
y+LAT1 and y+LAT2 for system y+L isoforms, asc-1 and asc-2 for system 
asc isoforms, xCT for system x–c isoforms, b0,+AT for system b0,+ isoforms, 
and AGT-1 for a system serving aspartate and glutamate transport (Table 
1.1). Moreover, reconstitution in liposomes shows that the light subunit 
b0,+AT is fully functional in the absence of the heavy subunit rBAT 
(Fernandez et al., 2002; Reig et al., 2002). HAT transport activities are, 
with the exception of system asc isoforms, tightly couplet amino acid 
antiporters, leading to exchange of amino acids (Palacin et al., 2005). 
The general features of amino acid transport activity are as follows 
(Wagner et al., 2001; Chillaron et al., 2001): 
• System L is a sodium-dependent transport of large branched and 
aromatic neutral amino acids in almost all type of cells;  
• System y+L is a sodium-independent transport of cationic amino 
acids and sodium-dependent transport for neutral amino acids (see 
section below); 
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• System asc is a sodium-independent transport for neutral amino 
acids of a small side chain, such as alanine, glycine, cystine and 
serine; 
• System x-c is a sodium-independent transport for cysteine and 
anionic amino acids; 
• System b0,+ is a sodium-independent transport for dibasic amino 
acids and neutral amino acids, including cystine; 
• System AGT-1 serves  aspartate and glutamate transport. 
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1.3 Transport activity of system y+L 
 System y+L was first functionally described in erythrocytes (Raul et 
al., 1998; Kanai et al., 2000). In polarized epithelia, system y+L is located at 
the basolateral membrane and allows for the efflux of cationic amino acids 
in exchange for preferably large neutral amino acids and sodium (Palacin et 
al., 2004; Palacin et al., 2005). This pattern of transport distinguishes 
system y+L from cationic amino acid transport y+ (CAT family) (Deves et 
al., 1998). On a molecular basis, two isoforms of system y+L have recently 
been identified, y+LAT1 and y+LAT2 (Torrents et al., 1998). Both subunits 
interact with 4F2hc to form the system y+L. 
 Human y+LAT1 is a protein consisting of 511 amino acids and its 
mRNA was found mainly in the kidney and small intestine (see below, 
section lysinuric protein intolerance, cap. 3). Functionally, y+LAT1 
transports cationic amino acids in absence of sodium and neutral amino 
acids in presence of sodium (Torrents et al., 1998). It seems that y+LAT1 
preferentially mediates the efflux of arginine, which may important in the 
kidney, where arginine is produced from citrulline and released into the  
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blood to supply the rest of the body with this amino acid (Palacin et al., 
2005). 
 The second isoform, y+LAT2, constitutes a protein of 515 amino 
acids. Expression of its mRNA was found in brain, testis, parotis and was 
found to be weaker in a small intestine, kidney, lung, liver and heart. 
y+LAT2 displays the same mechanism as y+LAT1 but tissues with lower 
transport capacity probably use y+LAT2 for transport of arginine (Broer et 
al., 2000).  
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Table 1.1. Heteromeric amino acid transporters 
Heavy 
Chain 
(HSHAT) 
Light 
Chain 
(LSHAT) 
HUGO 
Nomenclature 
Amino 
Acid 
Transport 
Human 
Chromosome 
Inherited 
Aminoaciduria
4F2hc  SLC3A2  11q13  
 y+LAT1 SLC7A7 y+L 14q11.2 LPI 
 y+LAT2 SLC7A6 y+L 16q22.1  
 LAT1 SLC7A5 L 16q24.3  
 LAT2 SLC7A8 L 14q11.2  
 asc-1 SLC7A10 asc 19q12-13  
 xCT SLC7A11 x-c 4q28-q32  
rBAT  SLC3A1  2p16.3 cystinuria 
 b0,+AT SLC7A9 b0.+ 19q12-13 cystinuria 
?      
 AGT1 SLC7A13 new 8q21.3  
 Asc-2 SLC7A12 asc not present  
Heteromeric amino acid transporters (HATs) are composed of a heavy and 
light nchain. Heavy subunits belong to solute carrier family SLC3, and light 
chain subunits belong to family SLC7. AGT and asc-2 heterodimerize with 
unknown heavy subunits. A functional asc-2 gene is not present in the 
human genome (from Palacin et al., 2005). 
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Figure 1.1: A heteromeric amino acid transporter. The heavy subunit 
(pink) and the light subunit (blue) are linked by a disulfide bridge with 
conserved cysteine residues (cysteine 158 for the human xCT and cysteine 
109 for human 4F2hc). (From Palacin et al., 2005). 
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Chapter 2 
 
 
PRIMARY INHERITED AMINOACIDURIAS 
 
 
 
2.1 Disease with Defective Amino Acid Transport 
 Primary inherited aminoacidurias (PIAs) are caused by defective 
amino acid transport activities, which affect renal reabsorption of amino 
acids and may also affect intestinal absorption of amino acids and transport 
function in other organs (Palacin et al., 2005). Several PIA have been 
described (Table 2.1):  
1. Reabsorption of dibasic or cationic amino acids is defective in:  
• lysinuric protein intolerance [LPI, also named hyperdibasic 
aminoaciduria type 2 or familial protein intolerance (MIM 222700) 
and first described by Perheentupa et al. (1965)] (Simell, 2001). This 
disorder will be the subject of the work presented in this thesis and it 
will be discussed in detail in the next chapter.  
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• autosomal dominant hyperdibasic aminoaciduria type I (MIM 
222690) (Whelan and Scriver, 1968).  
• isolated lysinuria (Omura et al., 1976).  
2. Reabsorption of cystine and dibasic amino acids is defective in: 
• cystinuria (MIM 220100) (Palacin et al., 2001). 
•  isolated cystinuria (MIM 238200) (Brodehl et al., 1967).  
3. Reabsorption of zwitterionic amino acids (i.e., neutral amino acids at 
physiological pH) is defective in: 
A. Hartnup disorder (MIM 234500) (Babu et al., 2003). 
B. Iminoglycinuria (MIM 242600) (Rosemberg et al., 1968).  
4. Reabsorption of glutamate and aspartate is defective in: 
• Dicarboxylic aminoaciduria (MIM 222730) (Melacon et al., 1977; 
Teijema et al., 1974).  
 
 
2.2 Renal reabsorption and intestinal absorption of amino acids 
transport  
 The renal reabsorption of amino acids occurs in the proximal  
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convoluted tubule (Silbernagl et al., 1983), and the absorption of amino 
acids occurs in the small intestine (Mariotti et al., 2000). Most of the 
transporters responsible for these functions are the same in kidney and 
intestine (Fig 2.1). The transporters with a role in reabsorption of amino 
acids are highly expressed in the corresponding apical or basolateral plasma 
membrane of the epithelial cells of the proximal of the proximal convoluted 
tubules (S1 and S2 segments) in kidney and of the enterocytes of the small 
intestine (Dave et al., 2004; Fernandez et al., 2002, Furriols et al., 1993). 
 
The molecular basis of cystinuria and LPI instructs us on the 
molecular bases of cystine and dibasic amino acid reabsorption. Mutations 
of the apical exchanger b0,+ (heterodimer rBAT-b0,+AT) lead to 
hyperexcretion of cystine and dibasic amino acids, as shown in human 
(Calonge et al., 1994; Feliubadalo et al., 1999), mouse (Feliubadalo et al., 
2003; Peters et al., 2003), and canine (Henthorn et al., 2000) cystinuria. 
Mutations of the basolateral exchanger y+L (heterodimer 4F2hc-y+LAT1) 
produce hyperexcretion of dibasic amino acids (Borsani et al., 1999; 
Torrents et al., 1999).  
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Similarly, there is intestinal malabsorption of cystine and dibasic 
amino acids in cystinuria and of dibasic amino acids in LPI (Simell 2001). 
Thus the sequential transport activities of systems b0,+ (apical) and y+L 
(basolateral) play a major role in renal and intestinal reabsorption of amino 
acids. Besides these two players, not much is known about other 
transporters with a role in dibasic amino acid reabsorption (Palacin et al., 
2004; Palacin et al., 2005). 
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     Table 2.1. Primary Inherited Aminoacidurias 
 Prevalence Type of Inheritance 
Trasport 
System 
LPI > 100 cases AR y+L 
Hyperdibasic 
Aminoaciduria 
Type 1 
very rare AD ? 
Isolated lysinuria very rare AR? ? 
Cystinuria 
Type 1 
Type 2 
1/7.000  
AR 
ADIP 
bo,+ 
Isolated cystinuria very rare AR? ? 
Hartnup disorder 1/30.000 AR B0 
Iminoglycinuria 1/15.000 AR ? 
Dicarboxylic 
aminoaciduria 
very rare AR? x-AG 
AR, autosomal recessive; ADIP, autosomal dominant with 
incomplete penetrance; AD, autosomal dominant; AR?, familiar cases 
in the few cases described for these disease suggest an autosomal 
recessive mode of inheritance (from Palacin et al., 2005). 
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Figure 2.1: Transporters involved in the renal and intestinal reabsorption of 
amino acids (from Palacin et al., 2005). 
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Chapter 3 
 
 
LYSINURIC PROTEIN INTOLERANCE 
 
 
 
3.1 Clinical aspects and biochemical investigations 
 Lysinuric protein intolerance (LPI; [MIM 222700]) represents a 
disease-model where mutations of the SLC7A7 gene, an amino acid 
transporter, give rise to variable and mostly unexplainable multiorgan 
involvement. LPI is a rare disorder relatively common in Finland, in Italy 
where more than 20 families have already been identified (Sperandeo et al., 
2000) and in Japan. LPI is an autosomic recessive dibasicaminoaciduria 
caused by defective cationic amino acid (CAA; L-arginine; L-lysine; L-
ornithine) transport at the basolateral membrane of epithelial cells in 
intestine and kidney (Simell, 2001; Palacin et al., 2001).  
 
The experiments of the Finnish group (Rajantie et al., 1980) suggest
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that system y+L is the main basolateral absorption system for dibasic amino 
acids in the small intestine: an oral load with the dipeptide lysyl-glycine 
increased glycine plasma concentrations, but plasma lysine remained almost 
unchanged in patients with LPI, whereas both amino acids increased in 
plasma of control subjects and in patients with cystinuria. This 
demonstrated the basolateral defect in LPI. Indeed, as a consequence of the 
renal and intestinal defects in LPI, plasma levels of dibasic amino acids are 
1/2 to 1/3 of normal levels (Simell, 2001). These results suggest that system 
y+L has a higher impact than system b0,+ on renal and intestinal reabsorption 
of dibasic amino acids. 
 
Arginine and ornithine are intermediates of the urea cycle that 
provide the carbon skeleton to the cycle. Their reduced availability results 
in a functional deficiency of the urea cycle. Protein malnutrition and 
deficiency of lysine, an essential amino acid, contribute to the patient's 
failure to thrive. LPI patients are usually asymptomatic while breast-
feeding; after weaning, the clinical findings include: vomiting, diarrhea, 
hepatosplenomegaly, bone marrow abnormalities, osteoporosis, episodes of  
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coma, mental retardation, lung involvement (mainly as alveolar 
proteinosis), altered immune response and chronic renal disease (Simell, 
2001; Palacin et al., 2001).  
 
 Metabolic derangement in LPI includes: reduced intestinal absorption 
of CAA, increased renal excretion of CAA and dysfunction of the urea 
cycle leading to hyperammonemia and orotic aciduria. The 
hyperammonemia occurs in inherited defect of urea cycle enzymes but may 
also results from lack of sufficient amounts of a urea cycle substrate, such 
as ornithine, in presence of normal enzyme activity. A lack of ornithine 
results in reduced synthesis of citrulline. Such a mechanism explains the 
hyperammonemia of LPI. The transport of citrulline in LPI is not affected. 
Thus the rationale for therapy with cytrulline in LPI is to provide the 
hepatocyte with limiting substrate for the urea cycle, allowing the cycle to 
function and also providing for large amounts of intracellular ornithine 
synthesis. Low-protein diet and citrulline supplementation are used to 
correct the functional deficiency of urea cycle, but this treatment, however, 
is insufficient to prevent severe complications such as renal and pulmonary  
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involvements. Recently, Simell's group reported correction of plasma lysine 
by oral supplementation with the amino acid (Lukkarinen et al., 2003).  
 
 
3.2 LPI complications 
Renal involvement and pulmonary alveolar proteinosis (PAP) represent 
life-threatening complications of LPI and almost nothing is known about 
their pathogenesis; Neither are new strategies for treatment of LPI patients 
available. Interestingly, after a heart-lung transplant for severe PAP-
associated respiratory insufficiency, an Italian LPI patient relapsed and died 
of respiratory failure (Santamaria et al., 2004). This unfortunate outcome 
suggests a pathogenetic role for alveolar macrophage in LPI-associated 
PAP. It also suggests that the lung itself is not affected by the defective y+L 
activity but it is likely the target of circulating cells (macrophages?). Severe 
morphological alterations, associated with a marked decrease in their 
number, have been described in pulmonary macrophages of LPI patients 
(Parto et al., 1993; Parto et al., 1994). The role of nitric oxide production 
from arginine in LPI macrophages seems to be a promising aspect of the 
pathogenesis of PAP as well as of other uncommon complications of the  
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disease such as recurrent pancreatitis and renal involvement (Furusu et al., 
1998; Al-Mufti et al., 1998). The arginine is also the precursor of important 
metabolic pathways such as nitric oxide (NO), polyamines, and creatine. 
Mutations of the SLC7A7 gene can give rise to a paradox: on one hand, low 
plasma levels of arginine cause vascular dysfunction through reduced NO 
production (Kamada et al., 2001); on the other hand, arginine could 
accumulate in polarized cells, for example in renal tubular cells, because of 
its defective efflux. This accumulation could cause an excessive production 
of NO that can bring to tubular damage as seen in experimental models of 
nephritis (Peter et al., 2003). 
 
 
3.3 Genetics 
 Putative cationic amino acid transporters were excluded as candidate 
genes for LPI (Incerti et al., 1994; Lauteala et al., 1997a; Sperandeo et al.,  
1998). The LPI gene was mapped to chromosome 14q11.2 by linkage 
analysis near to the T-cell receptor α/δ chains locus in Finnish families 
(Lauteala et al., 1997b). By same approach, a genetic homogeneity of LPI 
was demonstrated between Finnish and non-Finnish patients (Lauteala et  
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al., 1999). Recently, the LPI gene, SLC7A7 (solute carrier family 7A, 
member 7), located on chromosome 14q11.2 near the TCRA locus, has 
been identified and mutations were reported in LPI patients (Borsani et al., 
1999; Torrents et al., 1999). The human SLC7A7 gene contains 11 exons 
and 10 introns, harbouring ~20 kb of genomic DNA. The codon for the 
translation-initiator methionine is located in exon 3, whereas the 
termination codon is located in exon 11 (Sperandeo et al., 2000). An 
alternative RNA splicing in the 5’ untranslated region (caused by skipping 
of exon 2) has been found in SLC7A7 mRNA obtained from cultured 
lymphoblasts, fibroblasts and peripheral blood leukocytes (Noguchi et al., 
2000). SLC7A7 is expressed, among other tissues, in all tissues affected in 
LPI, as kidney, lung, small intestine and white blood cells (Borsani et al., 
1999; Torrents et al., 1999).  
  
SLC7A7 gene encodes the y+LAT1 protein, which belongs to the 
family of heteromeric amino acid transporters (HATs). The amino acid 
transporter is composed of a heavy chain subunit, 4F2hc, encoded by 
SLC3A2 gene, and of a light chain subunit, y+LAT1, linked to 4F2hc by a  
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disulfide bond (Chillaron et al., 2001). Co-expression of 4F2hc and y+LAT1 
induces sodium-independent and high affinity transport of CAA, known as 
y+L activity. When sodium is present, y+L is able to exchange CAA for 
neutral amino acids using an antiport mechanism. The y+LAT1 protein 
contains 12 putative transmembrane domains (TM) with the amino (N-) and 
carboxyl (C-) termini located inside the cell. 4F2hc is a type II membrane 
glycoprotein consisting of a single transmembrane domain with an 
intracellular N- terminus and a large extracellular C- terminus. In oocytes, 
SLC7A7 protein forms a ~135 kDa disulphide bond-dependent heterodimer 
with 4F2hc, which, after reduction with ß-mercaptoethanol, results in two 
peptides of ~85 kDa (4F2hc) and ~40 kDa (SLC7A7). SLC7A7 protein 
does not induce transport of CAA in Xenopus l. oocytes when injected 
alone, but y+L activity is detected when it is co-injected with 4F2hc 
(Torrents et al., 1998). There is evidence that the major function of 4F2hc is 
to traffic the complex to the plasma membrane and membrane topology of 
the heterodimer, whereas the transport itself is the function of the light 
chain (Chillaron et al., 2001). In absence of 4F2hc, the expression of the 
light chain is restricted to the Golgi area (Torrents et al., 1998). 
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The y+L activity is also exerted by another heterodimeric complex 
composed of 4F2hc and y+LAT2, the latter encoded by the SLC7A6 gene 
(Torrents et al., 1998). y+LAT1 and y+LAT2 share a high identity at both 
nucleotide and amino acid levels. y+LAT2 protein is more ubiquitously 
expressed than y+LAT1, including tissues such as small intestine and 
kidney where y+LAT1 is also highly expressed. Tissues and cell types with 
lower transport capacity probably use y+LAT2 to release arginine (Broer et 
al., 2000), explaining why y+L activity is not altered in fibroblasts and 
erythrocytes from LPI patients (Boyd et al., 2000; Dall'Asta et al., 2000). 
 
 
3.4 Mutations found in the SLC7A7 gene 
 A total of 31 SLC7A7 mutations have been described in 113 LPI 
patients originating from different countries (Palacin et al., 2005; Sperandeo 
et al., 2000; Sperandeo et al., 2005a). Identified SLC7A7 mutations include 
missense, nonsense, and splicing mutations, insertions, deletions and large 
genomic rearrangements. No LPI- associated mutations have been found in 
SLC3A2 gene (Sperandeo et al., 2005b). This strongly suggests that the  
SLC7A7 is the only gene involved as the primary cause of LPI. The most of  
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the LPI patients are homozygous for a specific mutation. In three patients, 
SLC7A7 mutation was detected in one allele only (Palacin et al., 2001; 
Sperandeo et al., 2005a). The LPI mutations are spread along the entire 
SLC7A7 gene (Table 3.1). The effect of some SLC7A7 mutations on y+L 
activity has been tested by expression in Xenopus oocytes. All mutant 
proteins fail to co-induce y+L transport when expressed with 4F2hc 
(Sperandeo et al., 2005a). Two mutations (G54V and L334R) have been 
reported as transport-inactivating mutations that are properly targeted to the 
plasma membrane (Mykkanen et al., 2000). By expression in Xenopus 
laevis oocytes and mammalian cells, the E36del mutant displayed a partial 
dominant-negative effect. The results reported by Sperandeo et al. (2005b) 
provide further insight into the molecular pathogenesis of LPI: a putative 
multiheteromeric structure of both [4F2hc/y+LAT1] and [4F2hc/y+LAT2], 
and the interference between y+LAT1 and y+LAT2 proteins (see section 
chapter 5). This interference can explain why the compensatory mechanism, 
i.e. an increased expression of SLC7A6 as seen in lymphoblasts from LPI 
patients, may not be sufficient to restore the y+L system activity. 
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Except for the Finnish mutation (IVS6-2A→T), only four others  
(1670insATCA, 1471delTTCT, W242X and R410X) were found in more 
LPI-independent families (Palacin et al., 2001; Sperandeo et al., 2000; Shoij 
et al., 2002). Surprisingly, in contrast to the single mutation found in 
Finnish LPI alleles, 10 different mutations were identified in LPI patients 
from Southern Italy, which suggests a higher mutational rate in this region 
without any reasonable explanation (Sperandeo et al., 2000; Sperandeo et 
al., 2005a). Data from Italian LPI patients suggest that the apparent 
worldwide rarity of this disease may be the result of under-diagnosis 
(Sperandeo et al., 2000). 
 
 
3.5 Genotype–phenotype correlation 
 A genotype–phenotype correlation for LPI cannot be established. As 
seen in Finnish and Italian LPI patients, the same genotype can give rise to 
extensive clinical variability (Borsani et al., 1999; Sperandeo et al., 2000). 
Furthermore, intrafamilial phenotypic variability has also been observed in 
Italian LPI patients all homozygous for the same mutation. Neither age at  
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onset of the disease nor compliance to treatment explain these differences in 
the clinical presentation. In addition to mutations of the SLC7A7 gene, 
other factors might have a role in the pathogenesis and clinical 
manifestations of LPI. 
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Table 3.1. List of SLC7A7 Mutations 
Nucleotide 
change in cDNA Effect 
Exon/ 
intron Ethnicity References 
Missense     
287A>C M1L EX3 Italian Sperandeo et. 2000 
435T>A M50K EX3 Italian Sperandeo et al. 2005a 
447G>T G54V EX3 Latvian, 
Estonian 
Mykkänen et al. 2000 
370T>C L124P EX3 Greek Sperandeo MP, 
unpublished 
740C>T F152L EX3 Greek Sperandeo et al., 2005b 
849C>T T188I EX4 Greek Sperandeo et al. 2005a 
999C>T S328F EX4 Japanese Shoji et al. 2002 
1284G>T R333M EX7 Turkish Sperandeo et al. 2005a 
1287T>G L334R EX8 Spanish Torrents et al. 1999, 
Mykkänen et al. 2000 
1299G>A G338D EX8 Swedish Mykkänen et al. 2000 
1444C>A S386R EX9 Italian Sperandeo et al. 2000 
1751T>C S489P EX11 Japanese Shoji et al. 2002 
Nonsense 
    
1012>A W242X EX4 Italian, 
Maroccan, 
North African 
Sperandeo et al. 2000; 
Mykkänen et al. 2000 
1514C>T R410X EX9 Japanese Noguchi et al. 2000 
1657C>A Y457X EX10 Greek, French Sperandeo et al. 2005a 
1703C>T R473X EX10 Australian Torrents et al. 2000 
Deletion 
    
242del543 Del of first 168 aa EX2 Italian Borsani et al. 1999 
381delGGA E36del EX3 Greek, 
Albanese 
Sperandeo et al. 2005a 
501delCTCT Frameshift after L71 EX3 Italian Sperandeo et al. 2000 
539delTT Frameshift after V84 EX3 Turkish Torrents et al. 2000 
786del125 Frameshift after I166 EX4 Pakistan Sperandeo et al. 2005a 
1291delCTTT Frameshift after L334 EX8 Spanish Torrents et al. 2000 
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Table 3.1. List of SLC7A7 Mutations (continued) 
 
Nucleotide 
change in cDNA Effect on translation 
Exon/ 
intron Ethnicity References 
Deletion 
    
1471delTTCT Frameshift after L395 EX9 Italian, 
German, 
Tunisian, 
Algerian 
Sperandeo et al. 2000; 
Mykkänen et al. 2000; 
Sperandeo  et al. 2005a 
1548delC Frameshift after F420 EX10 Arabic Mykkänen et al. 2000 
1630delC Frameshift after A448 EX10 Japanese Shoji et al. 2002 
1673delG 
 
Frameshift after A463 
 
EX10 
 
Japanese, 
Chinese 
Shoji et al. 2002 
Sperandeo et al., unpub. 
1746delG Frameshift after L486 EX11 
Dutch, 
Norwegian Mykkänen et al. 2000 
Insertion     
831insT Frameshift after L182 EX4 Italian Sperandeo et al. 2000 
1438insAACTA Y384X EX9 Canadian Mykkänen et al. 2000 
1670insATCA Frameshift after I461 EX10 Italian Borsani et al. 1999; 
Sperandeo et al. 2000 
Splicing 
Mutations     
IVS4+1G>A Skipping of EX4 Intron 4 Japanese, 
Turkish, 
Chinese 
Noguchi et al. 2000; 
Sperandeo et al. 2000 
Mykkänen et al. 2000 
Sperandeo et al., unpub. 
IVS6-2A>T Frameshift after V298 Intron 6 Finnish Borsani et al.1999; 
Torrents et 1999 
IVS7+1G>T No mRNA studies Intron 7 Japanese Sperandeo et al. 2000 
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Chapter 4 
 
 
EXPERIMENTAL WORK 
 
 
 
4.1 Outline of the Thesis 
 
 The overall aim of this Ph.D. thesis was the elucidation of the 
pathophysiology of LPI. Among all the genetic metabolic disorders, LPI is 
one of the most puzzling diseases. CAA depletion alone cannot to account 
for the multiorgan involvement caused by this disorder. 
Three different approaches have been designed to achieve this aim: 
 
1. Functional studies of SLC7A7 mutations 
2. Creation of mouse models of LPI 
3. Creation of a human cellular model of LPI 
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4.2 Principal results 
 
4.2.1. Functional studies of SLC7A7 mutations 
A) The first objective of this part of the thesis was a wider knowledge 
of the mutational spectrum of the SLC7A7 gene in LPI patients. The work 
done during the PhD program has led to the identification of eight 
additional novel mutations of SLC7A7 in six unrelated patients (Sperandeo 
et al., 2005a; Sperandeo et al., 2005b) (Table 4.1). All these mutations were 
identified by sequencing the entire coding region and exon-intron 
boundaries and by Southern blot, when necessary. Any kind of mutation 
(large genomic rearrangements, missense and nonsense mutations, splicing 
mutations, insertions and deletions), spread along the entire SLC7A7 gene, 
was found in LPI mutant alleles (Fig. 4.1). In a noteworthy case, an affected 
Turkish boy resulted to be homozygous for p.R333M (c.997G>T) mutation 
and  both parents heterozygous for this mutation. The c.997G >T change is 
located at the last nucleotide of exon 7 and apparently causes a missense 
mutation of the transcript (Fig. 4.2). In recent years, exonic nucleotidic 
changes, at specific position, have been shown to alter cis-elements that are  
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important for a correct splicing of the transcript (Carteggi et al., 2002). To 
test whether the p.R333M mutation affects the splicing mechanism, RT-
PCR was performed using total RNA extracted from fibroblasts and renal 
tubular cells isolated from the patient. In the fibroblast cell line, RT-PCR 
yielded two different products, the sequencing of which showed a full 
length transcript, which includes the c.997G >T mutation, and a shorter 
transcript where exon 7 is entirely skipped. In renal tubular cells, a more 
appropriate tissue for SLC7A7 expression studies, RT-PCR showed three 
different transcripts. Sequencing of the most abundant product disclosed the 
skipping of exon 7. The other two products presented either deletion of 
exons 7 and 9 or deletion of exons 6, 7 and 9 (Fig. 4.3). Therefore in renal 
tubular cells, exon 7 is always skipped and premature termination codons 
are introduced. These results have been reported in enclosed reprint in 
chapter 5. 
 
 Interestingly, this part of the project has also led to the diagnosis of 
LPI in countries where this disorder was almost unknown (Albania, Algeria, 
China, Greece, Pakistan, Tunis, Turkey). This suggests that the apparent  
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rarity of LPI outside Italy, Finland and Japan, is probably due to 
misdiagnosis of this disease due to the lack of a peculiar clinical 
presentation and early accessible diagnostic tests (Sperandeo et al., 2000; 
Sperandeo et al., 2005a; Sperandeo et al., 2005b). 
 
 B) The second objective of this part of the thesis was the study of the 
functional effects of SLC7A7 mutations. Therefore, most of the SLC7A7 
mutations have been functionally characterized by expression in Xenopus l. 
oocytes and by transfection in mammalian cell lines. For seven mutations, 
no arginine transport was observed when mutant cRNAs were co-injected 
with 4F2hc cRNA in Xenopus l. oocytes (Sperandeo et al., 2005a; 
Sperandeo et al., 2005b) (Fig. 4.4). However, two other mutations, E36del 
and F152L, found in a LPI compound heterozygote, provided further insight 
into the molecular pathogenesis of LPI. Expression studies in oocytes 
demonstrated that the F152L mutation moderately reduces y+L transport 
activity when compared to wt SLC7A7, whereas the E36del mutant 
dramatically interferes with the activity of both wt SLC7A7, F152L mutant 
and wt SLC7A6, displaying a partial dominant-negative effect. In addition, 
the deletion of the E36 residue does not alter the binding of the light chain  
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to 4F2hc and homing to the basolateral membrane as demonstrated by 
transfection into MDCK cells.  
 The results of the this study, reported in the enclosed reprint in 
chapter 6, provided further insight into the molecular pathogenesis of LPI: a 
putative multiheteromeric structure of both [4F2hc/y+LAT1] and 
[4F2hc/y+LAT2], and the interference between y+LAT1 and y+LAT2 
proteins. This interference could explain why the compensatory mechanism, 
(i.e. an increased expression of SLC7A6 as seen in lymphoblasts and renal 
tubular cells from LPI patients) may not be sufficient to restore the y+L 
system activity.  
 
 C) The third objective of this part of the thesis was the study of the 
biological role of other putative CAA transporters, such as SLC7A6 and 
4F2hc. By in silico analysis, we defined the genomic structure of SLC7A6, 
which covered a region of 60 kb on chromosome 16q13 and contained 11 
exons. No mutations of SLC7A6 were found in LPI patients sequencing all 
exons. These results reasonably exclude SLC7A6 as a modifier gene in LPI. 
Finally, 4F2hc cDNA was sequenced in eight independent LPI patients. No 
mutations were found thus excluding that the co-existence of 4F2hc  
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mutations might play a role in the phenotypic variability of LPI (Sperandeo 
et al., 2005b).  
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Table 4.1: Novel mutations identified in SLC7A7 gene. 
Base changea Amino 
Acid 
change 
Mutation type Exon 
c.106_106delGGA p.E36del Deletion 3 
c.149T>A p.M50K Missense 3 
c.370C>T p.L124P Missense 3 
c.453T>C p.F152L Missense 3 
c.563C>T p.T188I Missense 3 
IVS3_IVS4 // Deletion exon 4 // 
c.997G>T p.R333M Missense/splicing 
mutation 
7 
c.1371C>A p.Y457X Nonsense 10 
abase number according to the international nomenclature and 1 is the 
adenine of the initiator codon, Met. Nucleotide numbers are derived from 
SLC7A7 cDNA (GenBank reference sequence AF092032.1). 
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Figure 4.1: SLC7A7 mutations found in LPI patients. 
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Figure 4.2: c.997G>T (R333M) mutation. 
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Figure 4.3: Exon splicing of p.R333M RNA from patient. A) Deletion of 
exon 7 as found in mRNA from fibroblast and renal tubular cells; B) 
Deletion of exons 7 and 9 as found in mRNA from renal tubular cells; C) 
Deletion of exons 6, 7 and 9 as found in mRNA from renal tubular cells.  
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Figure 4.4: Functional analysis of y+LAT1 mutants in X. laevis oocytes.    
X. laevis oocytes were injected with with 4F2hc and either wt SLC7A7 or 
each mutant cRNA (molar ratio 1:1; 10 ng:10 ng). All SLC7A7 mutations 
abolished the L-arginine transport except for the F152L mutation, which 
caused an increase in L-arginine transport activity to 1.6 times that of the 
activity induced by 4F2hc expressed alone. 
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 4.2.2. Mouse models of LPI 
 
A. Slc7a7 null mouse. 
 
Generation of Slc7a7 null mouse 
 The objective of this part of the thesis was the creation of a murine 
model of Slc7a7 knock-out (Sperandeo et al., 2003; Sebastio et al., 2005; 
manuscript in preparation). As with most inherited disorders, an animal 
model is necessary to study both pathogenetic mechanisms of the disease 
and innovative therapeutic approaches.  
 The Slc7a7 gene maps to chromosome 14 (syntenic region of human 
chromosome 14). The amino acid sequence of the mouse and human 
proteins share high homology (90.4% identity; 98.6% similarity). Co-
immunoprecipitation experiments demonstrated that human 4F2hc forms 
disulfide-linked heterodimers with mouse y+LAT1 upon co-expression in 
Xenopus oocytes. In addition, there is clear evidence that mouse y+LAT1 
induces a system y+L activity (Peiffer et al., 1999). 
 A constitutive Slc7a7 knock-out mouse was generated by screening 
of the Omnibank library of mouse embryonic stem cell clones using the
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 Slc7a7 cDNA as a query (Lexicon Genetics Inc, Texas). The ES clones, 
containing the Slc7a7 gene, which was mutated by insertional mutagenesis 
using retroviral vectors, were identified and characterized (Fig. 4.5) 
(Zambrowicz et al., 1998).  
 
Embryo studies and histological examinations  
 Genotyping analysis of 606 offspring of Slc7a7 heterozygote matings 
revealed a non-Mendelian distribution of genotypes (28.4% wild type, 
68.6% heterozygotes, 3% null homozygotes), being the null allele 
underscored among the genotypes. Only two null mice survived whereas 16 
homozygotes died within 24 hours of birth and had a delayed pattern of 
growth. The proportion of Slc7a7 (-/-) pups was 8.3-fold lower (3%) than 
that expected by Mendelian transmission of a recessive trait (25%). This 
result indicated that the Slc7a7 (-/-) allele resulted in embryonic lethality. 
Gender did not influence the percentage of heterozygous animals, which 
also appeared healthy and fertile. They had no overt physiological 
disadvantage in appearance or somatic growth at maturity (body weight, 
behaviour, organ size) compared with their wild type littermates. To 
establish the timing of the observed embryo lethality of the null mouse, 
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numerous embryos from heterozygous crosses were collected at different 
embryonic stages (E16.5 and E18.5) and genotyped. We found that the 
percentages of (-/-), (+/-), and (+/+) embryos perfectly matched with a 
Mendelian distribution for a recessive trait. This expected Mendelian 
distribution suggests that most Slc7a7 (-/-) pups died within hours of birth 
due to maternal cannibalism. As a matter of fact at E 16.5 stage, the Slc7a7 
(-/-) embryos were already smaller than +/- or +/+ littermates and a few null 
mice observed at birth appeared less vital that unaffected pups (Fig. 4.6 a 
and b). None of the null embryos showed gross morphological 
abnormalities. Using anti-4F2hc antibodies, histopathological examination 
revealed differences in renal morphology. The embryos (-/-) showed a 
decreased number of glomeruli (Fig. 4.7). 
 
Adult Slc7a7 (-/-) mice: analysis of the phenotype 
 The only two surviving Slc7a7 (-/-) animals showed growth failure 
compared to their siblings since birth (Fig. 4.8). After weaning, they were 
fed on a low protein diet and citrulline supplementation. Both Slc7a7 (-/-) 
animals showed reduced fertility. The older animal, a male, survived until 
25 months of age, when the treatment with citrulline and low protein diet 
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was interrupted and then replaced by a normal diet. After 2 weeks, this 
animal presented hypotonia, tremors, progressive weight loss and died after 
2 weeks later. After an intercross with the Slc7a7 (-/-) male, the second 
animal, an 11-month-old female, had a pregnancy ended prematurely at 
E18.5 and cannibalised all the pups. The protein overload, probably, caused 
its death at 48 hours after delivery. By gross and histological studies both 
null animals did not display significant differences compared to wild type 
animals.  
 
Biochemical characterization of Slc7a7 (-/-) adult mice 
 To assess whether the CAA transport was altered in Slc7a7 (-/-) adult 
mice, CAA levels and orotic acid were measured in urine. Both Slc7a7 (-/-) 
mice showed an elevated excretion of arginine and ornithine in their urine 
when compared to wild type and Slc7a7 heterozygous animals (Fig. 4.9). 
No increased lysine excretion was found in affected animals when 
compared with wild type and heterozygous mice. This result might be 
explained by the extremely low intake of protein after weaning. In addition, 
this recalls what was reported in LPI patients when put on a restricted 
protein diet (Simell, 2001).  
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Expression studies by Real-time PCR 
 Real-time PCR was used to evaluate the relative abundance of 
mRNA in a set of selected genes involved in CAA transport (Slc7a1, 
Slc7a2, Slc7a6, Slc7a7, and Slc3a2), in arginine metabolism (Arg1, Arg2, 
Nos2) and in embryo growth (Igf1, Igf2, Igf2r). The expression of these 
genes was tested on mRNA, which was extracted from embryos and adult 
mouse tissues, and from placenta.  
 
Expression studies in placenta tissue 
 In placentas isolated from embryos Slc7a7 (-/-) at E18.5 age, the 
expression of Slc7a1, Slc7a2, Slc7a6 and Slc3a2 genes were identical to 
those observed in wild type embryos. In this tissue, the expression of 
Slc7a7 mRNA was 12.5 times lower than the controls, thus confirming the 
disruption of the Slc7a7 gene function (Fig. 4.10). 
 
Expression studies in Slc7a7 (-/-) embryo tissues 
 In selected tissues (intestine, kidney, lung, liver) of Slc7a7 (-/-) 
embryos (E18.5) mRNA Slc7a7 was markedly reduced compared to 
controls (Fig.4.11 a and b).  
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 As for genes involved in arginine metabolism, the expression of 
Arg1, Arg2 and Nos2 was tested. Interestingly, in liver tissues the Arg1 
expression was 5 times lower than that of wild type animals. In contrast 
Nos2 expression was up-regolated 8 times compared to wild type animals. 
The same results were also obtained for Slc3a2 (upregulated 2 times when 
compared to wild type animals) and for Slc7a6 (upregulated1.6 times when 
compared to wild type animals) (Fig. 4.11 a and b). 
 
Expression studies in Slc7a7 (-/-) adult tissues 
 Liver and lung tissues displayed up-regulation of Slc3a2 (2 times 
higher than wild type animals in both tissues), up-regulation of Slc7a6 (5.7 
and 3.3 times higher than wild type animals in liver and lung, respectively). 
We also found up-regulation of Arg1 in liver (2.5 times higher than wild 
type animals) and Arg2 in kidney (2 times higher than controls) (Fig. 4.12 a 
and b). 
 
Igf1, Igf2 and Igf2r assays in null embryos 
 To elucidate the pathogenesis of the severe intrauterine growth failure 
we tested the expression of Igf1 and Igf2 and Igf2r, which have a key role 
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in foetus-placental growth throughout gestation. Igf2 and Igf2r resulted in 
the down-regulation of Slc7a7 (-/-) placentas (Fig. 4.13). The Igfs and Igf2r 
were also down-regulated in all selected tissues from Slc7a7 (-/-) embryos 
(Fig. 4.14 a and b). 
 
 In conclusion, the Slc7a7 gene disruption was always associated with 
a severely delayed foetal growth, indicating the importance of this amino 
acid transporter’s role during embryonic growth (Sperandeo et al, 
manuscript in preparation). This severe reduced growth was also observed 
in Slc7a7 (-/-) adult mice. This is also a phenotypic characteristic seen in 
LPI patients due to protein malnutrition and a deficiency of essential amino 
acid such as lysine. Igf1, Igf2 and Igf2r were down-regulated in Slc7a7 (-/-) 
placenta and in target tissues (intestine, kidney, lung, liver) isolated from 
embryos E18.5. These results appear to be related to the disruption of the 
Slc7a7 gene function and could explain the severe reduced growth found in 
embryos and adult Slc7a7 (-/-) mice.  
 By Real-time PCR we found that the expression of Arg1 in liver 
tissue from Slc7a7 (-/-) embryos was down-regulated in contrast with the 
up-regulation of Nos2, whereas in the same tissue from adult null mice, we 
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found up-regulation of both genes. These results suggest that the 
accumulation of arginine into the cells, due to the defective efflux, might 
induce a temporally differentiated regulation of genes involved in the 
catabolism of the arginine.  
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Figure 4.5: Generation of KO mouse. Structure of the gene trap vector 
integration site in the Slc7a7 locus. The retroviral construct is inserted in 
the intron downstream from the ATG-containing Slc7a7 exon. Northern 
blot analysis of kidney RNA obtained from embryos at stage E18.5.The 
blot, hybridyzed with the entire Slc7a7 cDNA probe, shows signals in wt 
and Slc7a7 (+/-) embryos. Transcripts were undetectable in kidney RNA 
from Slc7a7 (-/-) embryos. 
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Figure 4.6: Growth rate and body morphology. a) wt (+/+) and KO (-/-) 
embryos at E18.5. b) wt (+/+) and KO (-/-) neonate pups. 
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Figure 4.7: Immunohistochemistry in kidney section. wt (+/+) and KO (-/-) 
embryos at E18.5. Slc7a7-/- embryo tissues display very low 4F2hc protein 
due to marked delay of renal development. 
 
 
 
 
 
 
-/-
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Figure 4.8: Growth rate and body morphology. wt (+/+) and KO (-/-) mice. 
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Figure 4.9: Biochemical characterization of Slc7a7 (-/-) adult mice. 
Metabolic derangement found in adult Slc7a7 (-/-) mice (urine from 2 
animals).   
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Figure 4.10: Expression of Slc3a2, Slc7a6 and Slc7a7 in placenta from 
embryos (-/-) at 18.5 stage vs controls. 
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Figure 4.11a: Expression of Slc3a2, Slc7a6, Slc7a7, Arg2 and Nos2 in 
selected tissues from embryos (-/-) at stage 18.5 vs controls. 
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Figure 4.11b: Expression of Slc3a2, Slc7a6, Slc7a7, Arg1 and Nos2 in 
selected tissues from embryos (-/-) at stage 18.5 vs controls. 
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Figure 4.12a: Expression of Slc3a2, Slc7a6 and Slc7a7 in selected tissues 
from adult mice (-/-) vs controls. 
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Figure 4.12b: Expression of Arg1, Slc3a2, Slc7a6 and Slc7a7 in selected 
tissues from adult mice (-/-) vs controls. 
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Figure 4.13: Expression of Igf1, Igf2 and Igf2r in Slc7a7 (-/-) placentas vs 
controls. 
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Figure 4.14a: Expression of Igf1, Igf2 and Igf2r in selected tissues of                    
Slc7a7 (-/-) embryos at stage 18.5 vs controls. 
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Figure 4.14b: Expression of Igf1, Igf2 and Igf2r in selected tissues of                    
Slc7a7 (-/-) embryos at stage 18.5 vs controls. 
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4.2.2. Mouse models of LPI 
 
B. Slc7a7 conditional mouse model 
 
Generation of a conditional LPI mouse model 
 With the exception of only 2 animals, our Slc7a7 (-/-) mouse model 
turned to be a lethal model, which prevented further studies. To circumvent 
this problem, a conditional Slc7a7 gene mouse model, is now being 
developed using the Cre/loxP recombination system, This conditional 
mouse will be generated by floxing exons 3 and 4 of the Slc7a7 gene and 
breeding with specific Cre-expressing strains (Fig. 4.15). We have already 
produced the vector with the LoxP sites flanking the ortholog genomic 
segments necessary for the recombination. The strategy of targeting vector 
construction required (Fig. 4.16): 
a. bioinformatic analysis of the mouse Slc7a7; 
b. amplification of the 2 arms of the vector (about 3 kb and 6 kb, 
respectively); 
c. 12 separeted subcloning along with screening by PCR, restriction 
analysis and sequencing of each subclone
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d. for each step of subcloning a further round of sequencing was 
required (total number of sequencing: 210 and synthesis of 52 
different primers).  
 With this strategy the molecular defect is expressed in a tissue-
specific way by specific intercrossing with mouse strains that selectively 
express the Cre-recombinase. A large number of tissue-specific Cre-
expressing mouse strains are already available 
(http://www.mshri.on.ca/nagy/cre.htm database). With this mouse model, 
single aspects of the disease can be investigated without the risk of a full-
blown clinical picture, which caused the lethality in the constitutive knock-
out mouse.  
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Figure 4.15: LPI conditional mouse model. Schematic representation of the 
Slc7a7 conditional mouse model strategy. 
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Figure 4.16: LPI conditional mouse model. Targeting vector construction 
strategy. 
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4.2.3. Creation of a human cellular model of LPI 
 The objective of this part of the thesis was the creation of a human 
cellular model of LPI in order to study the role of nitric oxide in the 
pathogenesis of the complications of the disease. Renal involvement is a 
life-threatening complication of LPI and almost nothing is known about its 
pathogenesis. A key-role might be played by unbalanced intracellular 
homeostasis of arginine. In fact, arginine is the precursor of important 
metabolic pathways leading to the synthesis of nitric oxide (NO), 
polyamines and creatine (Fig. 4.17). 
 
 Intestine and kidney are the main target tissues of LPI. While 
intestinal biopsy is an invasive procedure, often not allowed by parents, 
cultivation of renal tubular can serve as a tool to study SLC7A7 function in 
the target tissue.  Renal tubular cells (RTC) can be isolated and grown from 
patients with heavy shedding of these cells in urine (Inoue et al., 2000). We 
have set the methodologies for the isolation and for the cultivation of RTC 
from the urine of LPI subjects as well as patients with severe tubular 
nephropathy (Sperandeo et al., 2005c). Urine from these patients were 
collected and cells were selectively grown in an appropriate medium to  
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isolate those of renal tubular origin (Fig. 4.18). The origin of RTC was 
tested by immunohistochemical analysis (Fig. 4.19). In RTC from LPI 
patients we demonstrated very low level of SLC7A7 transcript as seen by 
Real-Time PCR. Moreover, CAA transport was tested in these cells and 
found to be defective as expected in LPI (Fig. 4.20).  
Therefore, RTC is the first cellular model where the functional defect of 
LPI has been demonstrated (sperandeo et al., manuscript in preparation).  
 
 The relationship between nitric oxide (NO) production and LPI seems 
to be an emerging aspect of this disorder. L-arginine is the substrate for the 
NO synthase-catalyzed reactions and its availability is crucial for the 
cellular rate of NO synthesis. Deficiency of arginine may lead to a decrease 
of NO production in vivo (Kayanoki et al., 1999). Markedly reduced 
endothelial-dependent vasodilation, via a decrease of NO production, was 
demonstrated in LPI patients (Kamada et al., 2001). On the other hand, 
increased levels of NO, through inducible oxide nitric synthase (NOS2), are 
fundamental in the pathogenesis of glomerulonephritis and pancreatitis, two 
clinical presentatios in LPI (Furusu et al., 1998; Al-Mufti et al., 1998). 
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 We investigated NO metabolism in RTC isolated from the urine of 
LPI patients and controls (Sperandeo et al., 2005c). NO production was 
investigated in RTC by flow cytometry and DAF-2 diacetate method after 
stimulation with arginine or citrulline load. Preliminary results indicate an 
overproduction of NO in LPI cells when compared to controls (Fig. 4.21). 
In addition, the effect of NO and oxidative stress on cell viability of these 
cells (apoptosis) was examined in parallel using flow cytometry. 
Preliminary results suggest that intracellular arginine accumulation induces 
necrosis in LPI cells (Fig. 4.22). 
 
 To investigate the fate of the arginine entrapped intracellularly, the 
expressions of ARG2 and NOS2, two key-enzymes of the arginine 
intracellular metabolism, were also studied by Real-Time PCR (Fig. 4.23). 
The results showed increased expression of both enzymes indicating a 
constitutional activation of both early and late repair phase of the 
inflammatory response as seen in experimental glomerulonephritis. 
Interestingly, also the expression of SLC7A6 mRNA, another gene exerting 
a y+L transport activity at the basolateral membrane, was higher than 
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controls. This might suggest an attempt to restore normal intracellular 
arginine levels.  
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Figure 4.17: Metabolic sources and fates of the arginine and citrulline. 
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Figure 4.18: Phenotype of renal tubular cells isolated from urine of LPI 
patients. 
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Figure 4.19: Immunohistochemical characterization of renal tubular cells. 
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Figure 4.20: Reduced y+L activity in renal tubular cells isolated from urine 
of LPI patients. 
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Figure 4.21: Overproduction of nitric oxide in renal tubular cells isolated 
from urine of LPI patients. 
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Figure 4.22: Apoptosis analysis in renal tubular cells isolated from urine of 
LPI patients. 
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Figure 4.23: Real-time PCR in renal tubular cells isolated from urine of 
two independent LPI patients vs controls. 
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4.3 Materials and Methods 
 
4.3.1 Cell cultures 
Skin fibroblasts were cultured using standard methods. Renal tubular 
cells were isolated from urine samples and cultivated according to Inoue 
et al. (2000). 
 
4.3.2 Mutation analysis of SLC7A7 gene 
All exons and intron-exon boundaries of the SLC7A7 gene were 
amplified from genomic DNA extracted from peripheral blood samples 
of all family members as previously reported (Sperandeo et al., 2000). 
Total RNA was extracted from fibroblast and renal tubular cells from 
patient homozygote for R333M mutation by guanidium/phenol method. 
First-strand cDNAs were synthesized by RT-PCR by SuperScript Rnase 
H-Reverse Transcriptase (BRL) and oligo(dt) as primer. Five µl of 
cDNA was amplified using a forward primer located in exon 5 (5’-
TGTTCTCCTACTCAGGCTGGG-3’) and a reverse primer located in 
exon 10 (5’-CAGAGGCAGAAGACAATCGG-3’). PCR products were 
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cloned into the pBluescript II SK- vector and sequenced by an 
automated system (ABI 377 DNA, Applied Biosystems, Monza, Italy).  
 
4.3.3 Generation of Mutant Constructs, expression in X. laevis oocytes 
and L-[3H] arginine uptake 
By using the Quick-Change site-directed mutagenesis kit (Stratagene, 
Amsterdam-Zuidoost, The Netherlands), seven mutant SLC7A7 cDNAs 
were constructed each containing one of the following mutations: 
p.M1L, p.E36del, p.M50K, p.F152L, p.T188I, p.W242X, p.S386R, 
p.Y457X, c.1185_1188delTTCT (previously known as 1471delTTCT). 
Oocytes (stage V and VI) from X. laevis females were isolated by an 
enzymatic procedure in Sperandeo et al. (1998).  Each oocyte was 
microinjected with either the wt SLC7A7 cRNA or each mutant cRNA 
together with 4F2hc (molar ratio 1:1; 10 ng:10 ng), using a microinjector 
device (Drummond Scientific Company, Broomall, PA, USA) as 
reported in Sperandeo et al.. (2005a). Data are showed as the mean ± SE 
of L-[3H] arginine uptakes in oocytes from 3 different frogs and 
expressed as a percentage of the L-[3H] arginine uptake as found in 
uninjected oocytes (control, 842±85.5 cpm ). 
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4.3.4 Arginine uptake assays in renal tubular cells  
Measurements of L-[3H] arginine uptake were obtained according to 
protocols described elsewhere (Dall’Asta et al., 2000). The uptake tudies 
were performed in collaboration with Prof. V. dall’Asta (Units of 
General and Clinical Pathology, Department of Experimental Medicine, 
Universita degli Studi di Parma, Parma, Italy). 
 
4.3.5 Immunostaining of renal tubular cells 
For immunofluorescence studies, renal tubular cells were plated into 
wells of 8-chamber slides (Nalge Nunc International Corp.,Naperville, 
USA). After 48-72 hours, cells were fixed with 4% paraformaldehyde 
for 5 min, permeated with 0.02% Triton X-100 for 15 min, and blocked 
with 10% bovine serum albumin for 1 hours. Cytokeratin 7, Carbonic 
Anhydrase II and Carbonic Anydrase IV proteins were detected using 
specific antibodies. Nuclei were counterstained by DAPI (Roche, 
Germany; g/l, dilution 1:4000), and cells were examined by 
fluorescence microscopy (Zeiss Axioscope 2 equipped with Axiovision 
camera) with appropriate filters. Digital images were saved and analyzed 
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with Adobe PhotoShop (Adobe Systems Inc., Mountain View, 
California, USA). 
 
4.3.6 Mouse care and treatment 
Mice were housed at 24°C on a fixed 12-hour light/ 12-hour dark cycle 
and had free access to water and rodent chow. All Slc7a7 (-/-) mice were 
fed with a diet containing 8% protein (a special diet produced ad hoc by 
Mucedola, Italy) and citrulline supplementation (100 mg/mL solution; 
administered at 100 µg/g of body wieght/die) (SIGMA). 
 
4.3.7 Genotyping of Slc7a7 embryos and mice colony 
Genomic DNA was extracted by standard protocols from tail biopsies 
isolated from 3-week old progeny of matings and from E (embryonic 
day) 16.5 and 18.5 embryos. A PCR method was used with primers that 
recognize Slc7a7 alleles on mouse chromosome 14. The oligonucleotide 
primers used were:  
A: 5’-GATGAAGTGATCCTAGC CGTAG-3’;  
B: 5’-GCAGCTCTATGTCACAGGGCG-3’; and  
LTR2 5’-AAATGGCGTTACTTAAGCTAGCTTGC-3’.  
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These primers are located in intron 3 of the Slc7a7 gene, surrounding the 
gene-trap insertion site. About 100 ng of purified from mice and 
embryos tail genomic DNA was used as template for PCR in a 25 µl 
reaction volume. PCR conditions were: 94°C for 1 min, 55°C for 1 min, 
72°C for 1 min for 39 cycles.  
 
4.3.8 Animal experiments 
Two groups of mouse embryos were used for this study. One group 
consisted of three wild type animals that were killed at E16.5 and E18.5. 
Another group consisted of three Slc7a7 (-/-) killed at same embryonic 
age.   
Two groups of adult mice were used for this study. One group consisted 
of three wild type adult animals and another group consist of two Slc7a7 
(-/-) adult mice.  
 
4.3.9 Gross and immunohistochemical studies  
Whole mount embryos and selected tissues such as intestine, liver, lung 
and kidney, isolated from embryos and adult mice, were fixed by 
immersion in 4% parafolmaldeyde for 24-48 hours. After fixation, 
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tissues were routinely processed and embedded in paraffin. In summary, 
4 mm sections were deparaffined in xylene and rehydrated and then 
stained with hematoxylin and eosin for morphological assessment. For 
immunohistochemical studies, the endogenous peroxidase activity was 
blocked by incubation in 3 % hydrogen peroxide (SIGMA) in PBS for 
10 min. Sections were washed in TBS, then blocked with 10% BSA for 
1 hour at room temperature (RT). The primary antibody, goat anti-
mouse CD98 (Santa Cruz, Biotechnology, Santa Cruz, CA, USA), was 
diluted 1:200 in TBS containing 2% BSA for 1 hour at RT. Slides were 
washed in TBS, then incubated with the biotinylated secondary 
antibody, rabbit anti goat (Dako) diluted 1:200 at RT for 1 hour. Bound 
antibodies were detected by an avidin-biotin complex method (Sigma) 
with 3’, 3’-diaminobenzidine as chromogenic substrate following the 
manufacturer’s instructions (SIGMA). Negative controls were included 
in each experiment by omission of the primary antibody. After 
counterstaining of nuclei with hematoxylin, sections were mounted with 
aquamount (BDH). The sections were viewed with a Nikon microscope. 
Pictures were processed and assembled using Adobe PhotoShop. 
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To prevent observer bias, all histological specimens were coded and 
examined without knowledge of animal age and genotype. 
 
4.3.10 Real time PCR 
Real time PCR was performed according to the reccomendation supplied 
by Applied Biosystems (http://europe.appliedbiosystems.com/). For all 
genes of interest, primers were purchased from Applied Biosystems as 
‘AssaysOnDemand®. Primers were chosen to result in amplicons of 70-
150 bp that span intron-exon boundaries to avoid the effect of potentially 
contaminating genomic DNA. A 25 µl PCR reaction volume was 
prepared using 2 µl (about 40 ng) cDNA as template with sense and 
antisense primers and the labelled probe. Reactions were run in 96-well 
optical reaction plates using an Applied Biosystems 7300 Real-Time 
PCR System. Thermal cycles were set at 95°C (10 min) and then 35 
cycles at 95°C (15 sec) and 60°C (1 min) with auto ramp time. For 
analysing the data, the threshold line was set automatically and it was in 
the linear range of the amplification curves for all mRNA in all 
experimental runs. All reactions were performed in triplicate. The 
abundance of the target mRNAs was calculated relative to a reference 
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mRNA (b2 microglobulin). Relative expression ratios were calculated as 
R=2(Ct(b2 microglobulin)-Ct(test)), where Ct is the cycle number at the threshold 
and the test stands for the tested mRNA. The interval of confidence was 
fixed at 95%. 
 
4.3.11 Urine collection and analysis 
From each experimental animal, urine was collected in a mouse 
metabolic cage (Momoline, Italy) after a 2-day adaption period. Twenty-
four-hour urine was collected and immediately frozen. Amino acid 
levels and orotic acid content were performed by GC–MS analysis in 
collaboration with Prof. G. Corso  (Federico II University, Naples, Italy 
and  University of Foggia, Foggia, Italy) . 
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Chapter 7  
 
 
DISCUSSION  
 
 
 
 The overall aim of the present thesis is to contribute to the elucidation 
of the pathophysiology of LPI. LPI is a congenital aminoaciduria caused by 
a defective transport of CAA to the basolateral membrane of the epithelial 
cells of the intestine and the kidney. In the last 6 years, that is to say after 
the isolation of the gene, no further progress on the knowledge of the 
molecular bases of the LPI pathophysiology has been achieved. The 
therapeutic approach has not changed despite the emerging suspicion that 
an excess of citrulline might worsen the renal involvement.  
 
 Among all the genetic metabolic disorders, LPI is one of the most 
puzzling diseases, where CAA depletion alone is insufficient to account for 
the multiorgan involvement. 
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Three different approaches were taken to study the molecular bases of the 
LPI pathophysiology: 
1. Functional studies of SLC7A7 mutations 
2. Creation of mouse models of LPI 
3. Creation of a human cellular model of LPI 
 
 Our functional data favour a different model for the y+L transporter: a 
multiheteromeric structure composed of heterodimers of 4F2hc and 
y+LAT1. Accordingly, a severe y+LAT1 mutant, e.g. E36del, might 
interfere with the function of the complex even in presence of a second mild 
mutant allele, e.g. F152L.  
 A multiheteromeric structure of the y+L transporter would be also in 
agreement with a similar model (heterotetrameric structure) recently 
proposed for [rBAT/b0,+AT] complex  the transport system defective in 
cystinuria, a cognate disorder of LPI.  
 Phenotypic variability is an unresolved problem for most genetic 
disorders. In this respect, LPI is a remarkable example. After the 
identification of the mutated gene in this disease, efforts aimed at 
establishing a genotype/phenotype correlation were unsuccessful. To further 
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complicate this point, the molecular physiology of amino acid transport is 
finely tuned by a large number of specific carriers, which often exhibit 
similar tissue specificity and biochemical features. The efflux of CAA from 
cells is under the action of y+L system, which is exerted by at least two 
transporters, [4F2hc/y+LAT1] and [4F2hc/y+LAT2] respectively. In 
addition, y+LAT2 and 4F2hc are almost ubiquitously expressed in 
mammalian tissues, including small intestine and kidney. As a consequence, 
one wonders why LPI can turn out to be a life-threatening disease despite 
the presence of an almost ubiquitous [4F2hc/y+LAT2] complex. Our data 
show that the activity of the [4F2hc/y+LAT2] complex can be influenced by 
the presence of severe y+LAT1 mutants such as E36del. The y+L transport 
activity is unaffected in erythrocytes and fibroblasts of LPI patients. This 
can be explained by a predominant or exclusive expression of y+LAT2 in 
those cells. In other tissues, such as small intestine and kidney, where both 
SLC7A6 and SLC7A7 are expressed, y+LAT1 mutants might interfere with 
the activity of the [4F2hc/y+LAT2] complex. This interference could 
explain why the compensatory mechanism (i.e. an increased expression of 
SLC7A6 as seen in lymphoblasts or in RTC from LPI patients) may not be 
sufficient to restore the y+L system activity. 
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 It is still unclear why Finnish LPI patients, all affected by the same 
SLC7A7 genotype, also present a wide phenotypic variability. We excluded 
the possibility that concomitant mutations of the coding region of either 
SLC7A6 or 4F2hc might be related to the phenotypic variability in eight 
LPI patients. However, we could not rule out differences of gene expression 
of either SLC7A6 or 4F2hc.  
 
 An animal model of LPI is nevertheless essential since the 
complexity of the pathology and obvious ethical issues prevent some 
experimental work in humans. The first animal model of LPI, a constitutive 
knock-out of Slc7a7, was generated to study the pathophysiology of LPI 
and to explore new therapeutic protocols. Currently, we have succeeded in 
generating this model but it has turned out to be lethal in the perinatal 
period. Such lethality limited our studies. To circumvent this problem, we 
are generating a conditional Slc7a7 gene mouse model using the Cre/loxP 
recombination system. With this mouse model single aspects of the disease 
can be investigated without the risk of a full-blown clinical phenotype, 
which had caused the lethality in the constitutive knock-out mouse.  
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 The production of a human cellular model of the LPI, namely a renal 
tubular cellular model, is a useful approach to study the role of nitric oxide 
in the pathogenesis of renal complications of the disease. Renal 
involvement represents a severe complication of LPI and almost nothing is 
known about its pathogenesis. The crucial role might be played by an 
unbalanced intracellular homeostasis of arginine, which is the precursor of 
important metabolic pathways such as nitric oxide (NO), polyamines and 
creatine. Mutations of the SLC7A7 gene can give origin to a paradox: on 
one hand, low plasma levels of arginine cause vascular dysfunction through 
reduced NO production; on the other hand, arginine could accumulate in 
polarized cells, for example in renal tubular cells, because of its defective 
efflux. Furthermore the arginine metabolism studies on RTC could be 
crucial for gaining knowledge of renal involvement in LPI. Our preliminary 
results have demonstrated that this accumulation is due to a defective efflux 
which can cause an excessive production of NO resulting in tubular damage 
(necrosis) as seen in experimental models of nephritis. In addition, the 
arginine is also synthetized from citrulline in a pathway known as the 
arginine-citrulline pathway (see fig. 4.16). Our results demonstrated that 
overload of citrulline (supplemented daily in agreement with conventional 
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therapeutic protocols for LPI patients) in RTC might represent a factor that 
leads to an even greater arginine overload in renal tubuli.  
 
 The work described in this thesis has led to the following 
conclusions: 
1. putative new model of y+L transporter with a putative 
multiheteromeric structure; 
. 2. ablation of Slc7a7 causes severe prenatal growth retardation with 
no gross developmental abnormalities but with unbalanced NO 
metabolism; 
. 3. unbalanced NO metabolism might be the key to understand the 
pathophysiology of many complications of LPI in man; 
. 4. renal involvement in human LPI has a clear relationship with 
apoptosis induced by high levels of NO synthesis in renal tubular 
cells; 
. 5. conventional therapeutic protocols of LPI should be revised 
immediately in order to avoid excessive citrulline intake and possible 
iatrogenic complications arising from disease. 
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Summary  
 
 
Background: Lysinuric protein intolerance (LPI; MIM 222700) is caused 
by a defective transport of cationic amino acids (CAA for Cationic Amino 
Acids) to the basolateral membrane of the epithelial cells of intestine and 
kidney. Clinical manifestations of LPI include:vomiting, diarrhea, stunted 
growth, visceromegaly, osteoporosis, episodes of coma, mental delay, 
severe pulmonary (pulmonary alveolar proteinosis, PAP) and renal 
involvements. The metabolic derangement of this disease includes: reduced 
intestinal absorption of CAA, increased CAA renal excretion and 
impairment of the urea cycle that brings to hyperammonemia and increased 
orotic aciduria. The molecular basis of LPI is a defective transport of CAA 
normally exerted by system y+L. The y+L activity is induced by a 
heterodimer composed of:  
• the heavy chain 4F2hc, encoded by the SLC3A2 gene; 
• a light chain that can be either y+LAT1 (encoded by the SLC7A7 
gene) or y+LAT2 (encoded by the SLC7A6 gene).  
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We found that the SLC7A7 gene is mutated in LPI patients and we also 
characterized most of the mutations found so far in Italian and non-Italian 
patients. 
Specific objectives: The overall aim of the present thesis is to contribute to 
the elucidation of the pathophysiology of LPI, using three different 
approaches:  
1. Mutational analysis of LPI patients;  
2.  Functional studies of SLC7A7 mutants;  
3.  Creation of animal and cellular models of LPI.  
Results: Our functional results revealed a new scenario in the knowledge on 
LPI disorder. In fact, our results provide further insight into the molecular 
pathogenesis of LPI: a putative multiheteromeric structure of both 
[4F2hc/y+LAT1] and [4F2hc/y+LAT2], and the interference between 
y+LAT1 and y+LAT2 proteins. This interference can explain why the 
compensator mechanism (via an increased expression of SLC7A6 seen in 
lymphoblasts and renal tubular cells from LPI patients) may not be 
sufficient to restore the y+L system activity. 
The first animal model of LPI, a constitutive knock-out of Slc7a7, has been 
generated to study the pathophysiology of LPI and explore new therapeutic 
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protocols. At the moment, we have succeeded in generating this model but 
it turned out to be lethal in the perinatal period. This lethality limited our 
studies. To circumvent the problem, we are generating a conditional Slc7a7 
gene mouse model, using the Cre/loxP recombination system. With this 
mouse model, single aspects of the disease can be investigated without the 
risk of a full-blown clinical phenotype, which caused the lethality in the 
constitutive knock-out mouse.  
The first cellular model of LPI was obtained by isolation of renal tubular 
cells from urine of LPI patients. Using this cellular model we studied the 
relation between renal compliance and the nitric oxide metabolism. Our 
preliminary results confirm a possible relation between production of nitric 
oxide and renal involvement known in LPI. 
Conclusions: The work described in this thesis has led to the following 
results: 
1. putative new model of y+L transporter with a putative 
multiheteromeric structure; 
2. ablation of Slc7a7 causes severe prenatal growth retardation with no 
gross developmental abnormalities but with unbalanced NO 
metabolism; 
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3. unbalanced NO metabolism might be the key to understand the 
pathophysiology of many complications of LPI in man; 
4. renal involvement in human LPI has a clear relationship with 
apoptosis induced by high levels of NO synthesis in renal tubular 
cells; 
5. conventional therapeutic protocols of LPI should be revised 
immediately in order to avoid excessive citrulline intake and possible 
iatrogenic complications arising from disease. 
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